H.C. Wainwright analyst Brandon Folkes initiated coverage of Rein Therapeutics (RNTX) with a Buy rating and $10 price target The shares can outperform over the next 12 months given the company’s “potential best-in-class pipeline,” the analyst tells investors in a research note. The firm expects the biggest share catalyst to be the initial data readout of the Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNTX:
- Rein Therapeutics announces publication of data on LTI-03 in IPF
- Rein Therapeutics Secures Second Advance in Funding Deal
- Rein Therapeutics files to sell 10M shares of common stock for holders
- Home Depot reports Q2 results, SoftBank invests $2B in Intel: Morning Buzz
- Palo Alto upgraded, Li Auto downgraded: Wall Street’s top analyst calls